TOKYO -- Fujifilm Holdings aims to roughly double sales in its health care business to crack 1 trillion yen ($9.24 billion) in the next several years, seeking to build a new reliable income driver as its mainstay copier business stagnates.
The Tokyo-based company wants to win more orders to develop biopharmaceuticals on a contract basis while also focusing on medical equipment and information systems for hospitals, Chairman and CEO Shigetaka Komori said in an interview with Nikkei.
The target of 1 trillion yen in sales by the mid-2020s, along with 100 billion yen in operating profit, is "achievable through acquisitions and growth of existing products," Komori said. For the current fiscal year to next March, the health care segment is expected to ring up 510 billion yen in sales, up 5% on the year, and earn 44 billion yen in operating profit for a 32% gain.
The market for biotech contract development and manufacturing organizations has been growing amid the surging demand for biopharmaceuticals. Fujifilm is updating its equipment and developing effective culture technology to win business from drugmakers looking to outsource their operations.